EAM
CMTA

Eventide Asset Management’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Eventide Asset Management’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-60,000
Closed -$1.14M – 154
2017
Q4 		$1.14M Hold
60,000
– – 0.06% 125
2017
Q3 		$1.01M Buy
+60,000
New +$981K 0.06% 121

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Eventide Asset Management's CMTA Position: Q1 2018 in Review

Eventide Asset Management sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q1 2018, closing a stake of 60,000 shares — an estimated $1.14M sold.

Eventide Asset Management first reported a position in CMTA in Q3 2017 and held it in 2 quarters. The position peaked at $1.14M in Q4 2017. 38 funds tracked by Wall St. Rank hold CMTA as of Q1 2018.

  • Eventide Asset Management reported no remaining Clementia Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • Eventide Asset Management sold 60,000 Clementia Pharmaceuticals Inc. shares in Q1 2018, an estimated $1.14M.
  • Eventide Asset Management first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 2 quarters.
  • Eventide Asset Management's Clementia Pharmaceuticals Inc. position peaked at $1.14M in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q1 2018.

Based on Eventide Asset Management's 13F filing for Q1 2018, filed 15 May 2018.